FDA approves Tecentriq and Tecentriq Hybreza as the first ctDNA-guided adjuvant therapy for muscle-invasive bladder cancer following cystectomy, supported by Phase III IMvigor011 data showing improved disease-free and overall survival in ctDNA-positive patients.
Written By: Sana Khan, BPharm
Reviewed By: Pharmacally Editorial Team
The U.S. Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) as adjuvant treatment options for adults with muscle-invasive bladder cancer (MIBC) who have circulating tumor DNA molecular residual disease (ctDNA MRD) following cystectomy, as identified by Signatera CDx developed by Natera.
The approval marks the first FDA authorization of a ctDNA-guided therapy approach in oncology, allowing clinicians to identify patients at high risk of recurrence after surgery and selectively offer adjuvant immunotherapy while avoiding unnecessary treatment in patients without detectable molecular residual disease.
The FDA decision was supported by results from the global Phase III IMvigor011 study (NCT04660344), a randomized, double-blind, placebo-controlled trial evaluating adjuvant Tecentriq in patients with MIBC who tested positive for ctDNA MRD after cystectomy. Patients first entered a surveillance phase involving serial ctDNA monitoring for up to one year after surgery. Only patients who tested positive for ctDNA during surveillance were randomized to receive either Tecentriq or placebo, making the study one of the first prospective Phase III trials to use a molecular residual disease-guided treatment strategy.
In the study, Tecentriq reduced the relative risk of disease recurrence or death by 36% for disease-free survival (DFS) and reduced the relative risk of death by 41% for overall survival (OS) compared with placebo in ctDNA-positive patients. No new safety signals were reported, and the safety profile was generally consistent with previous studies of Tecentriq.
According to Genentech Chief Medical Officer Levi Garraway, combining immunotherapy with molecular residual disease testing may help physicians identify patients who are most likely to benefit from treatment while sparing others from unnecessary therapy.
Meri-Margaret Deoudes, CEO of the Bladder Cancer Advocacy Network, said the ctDNA-guided strategy could help reduce uncertainty during post-surgical monitoring by identifying patients at higher risk of recurrence earlier and enabling faster treatment decisions.
Muscle-invasive bladder cancer is an aggressive form of bladder cancer that spreads into the muscle layer of the bladder wall. More than 150,000 people worldwide undergo bladder removal surgery for MIBC each year, yet nearly half experience disease recurrence following surgery. Historically, treatment decisions after cystectomy have relied largely on tumor staging. The IMvigor011 study instead used personalized ctDNA testing to detect molecular evidence of residual cancer in blood samples before recurrence became visible on imaging scans.
The surveillance phase of IMvigor011 enrolled 761 patients who underwent serial ctDNA testing after cystectomy. Among them, 250 patients who tested positive for ctDNA entered the treatment phase and were randomized to receive either Tecentriq or placebo. The study’s primary endpoint was investigator-assessed disease-free survival, while secondary endpoints included overall survival and tolerability.
Tecentriq is a monoclonal antibody designed to target PD-L1, a protein expressed on tumor cells and tumor-infiltrating immune cells. By blocking PD-L1 interactions with PD-1 and B7.1 receptors, the therapy may help reactivate T-cell responses against cancer cells. In addition to bladder cancer, Tecentriq is also approved in multiple oncology indications, including in combination with Zepzelca as maintenance treatment for extensive-stage small cell lung cancer.
Reference
About the Writer
Sana Jamil Khan (LinkedIn) is a B. Pharm graduate with a strong interest in medical writing and scientific communication. Her work focuses on interpreting clinical research, exploring developments in pharmaceutical science, and presenting complex medical information in a clear and accessible manner. She is particularly interested in topics related to human clinical studies, drug safety observations, and emerging therapeutic research.